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Abstract
OBJECTIVE: To investigate the effect of black cate-
chu (BC) on the pharmacokinetics of theophylline
(CYP1A2 substrate, with narrow therapeutic index)
in rabbits.
METHODS: In the present investigation the effect
of BC on the pharmacokinetics of theophylline, a
CYP1A2 substrate was determined. In the study, BC
(264 mg/kg, p. o.) or saline (control group) was giv-
en to rabbits for 7 consecutive days and on the 8th
day theophylline (16 mg/kg) was administered oral-
ly one hour after BC or saline treatment. Blood sam-
ples were withdrawn at different time intervals (0.5,
1, 1.5, 2, 3, 4, 6, 8, 12, 24 and 36 h) from the margin-
al ear vein.
RESULTS: The pretreatment of rabbits with BC re-
sulted in a significant increase in maximum blood
concentration, time of peak concentration and area
under the concentration time profile curve until
last observation which was about 41.32% , 35.71%
and 15.03%, respectively. While decreases in clear-
ance, volume of distribution, and half-life were ob-
served. It is suggested that BC pretreatment de-
creases the CYP1A metabolic activity leading to in-
crease in bioavailability and decrease in oral clear-
ance of theophylline, which may be due to inhibi-
tion of CYP1A.
CONCLUSION: BC can significantly alter theophyl-
line pharmacokinetics in vivo possibly due to inhibi-
tion of CYP1A and P-glycoprotein activity. Based on
these results, precaution should be exercised when
administering BC with CYP1A substrate.
© 2015 JTCM. All rights reserved.
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INTRODUCTION
Theophylline is a narrow therapeutic index anti-asth-
matic drug,1,2 with a high inter-individual variation
in plasma concentration. Plasma concentrations be-
low 10 µg/mL may be associated with inadequate ther-
apy, while those above 20 µg/mL may cause potential
serious side effects in humans.3 Theophylline is primari-
ly oxidized by cytochrome P450 (CYP)1A and to lesser
extent by CYP2E of the hepatic microsomal mono-oxy-
genase system via N-demethylation and 8-hydroxyl-
ation pathways, respectively.4-6 Hence, it could be ex-
pected that the pharmacokinetic parameters of theoph-
ylline could be changed on pretreatment of drugs or
herbal medicines which affect the activity of CYP1A.
Therefore, drug-drug or herb-drug interactions may af-
fect the therapeutics of theophylline.7 The inhibition of
CYPlA2 activity may increase plasma theophylline con-
centration by inhibiting hepatic clearance and may con-
tribute to the emergence of adverse effects. In contrast,
induction of CYP1A2 may reduce plasma theophylline
to sub-therapeutic concentrations. The majority of seri-
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ous cases of drug interactions are result of the interfer-
ence of the metabolic clearance of one drug by another
co-administered drug, food or natural product. To
date, research regarding drug-herb interactions is limit-
ed mostly to case reports and a few systematic re-
views.8-14 Herbal drug supplements in world have tradi-
tionally been used alone or in combination with pre-
scribed drugs for the treatment of several medical ill-
nesses.15,16 In addition, people with asthma are likely to
select alternative therapy, including herbal medicine.17
Briefly, BC is a dried aqueous extract of tree heartwood
of Acacia catechu (Family: Fabaceae). BC contains
high amount of tannins and flavonoids such as cate-
chin and catechu tannic acid, epicatechin, Atzelchin,
catechin tetramer, dicatechin, gallochin, gossypetin,
phlobatannin, kaempferol and quercetin.18 It is report-
ed that heartwood extract has various pharmacological
effects like immunomodulatory, anti-pyretic, hepato-
protective and antioxidant activity.19-22 Medicinal use of
Acacia catechu is confined to traditional or folk medi-
cines especially in Asia. It is the main ingredient of Pan
Masala and Gutka. The consumption of Pan masala
and Gutka is common to Indian subcontinent as well
as by immigrant communities settled in Middle-east,
gulf countries, Europe and the united states.23-26 It is re-
ported that 46% of the residents of a local community
inKarachi, Pakistan are habitually of chewing gutka.23,24
So far, there is a dearth of literature of metabolic inter-
actions between BC and clinically used drugs. This
study attempted to investigate the effect of BC on the
pharmacokinetics of theophylline (CYP1A2 substrate,
with narrow therapeutic index) in rabbits.
MATERIALS ANDMETHODS
Materials
Theophylline and hydroxyethyl theophylline (internal
standard; IS) were obtained from BASF (Ludwig-
shafen, Germany) and Sigma-Aldrich (St. Louis, MO,
USA) respectively. High performance liquid chroma-
tography (HPLC) grade acetonitrile was procured from
Merck (Darmstadt, Germany). BC extracts cakes were
purchased from local market in Riyadh, Saudi Arabia.
HPLC grade water was procured by Milli-Q purifica-
tion system (Millipore, Bedford, MA, USA). All other
reagents used were of analytical grade.
Animals and study design
Ten healthy white rabbits, weighing 3-4 kg, were ob-
tained after the study was duly approved by the Experi-
mental Animal Care Center, College of Pharmacy,
King Saud University, Riyadh, Saudi Arabia, and main-
tained in accordance with the recommendations of the
Guide for the Care and Use of Laboratory Animals
approved by the center (NIH publications No. 80-23;
1996). All animals were maintained under standard
laboratory conditions of a 12-h light/dark cycle at (25
± 2) ℃, and given pellet diet with water ad libitum and
fasted overnight prior to the experiments.
The animals were randomly divided into two groups, a
control group and a theophylline + BC group, five ani-
mals in each group. In the control group, rabbits were
given saline water for 7 consecutive days and on the
8th day theophylline (16 mg/kg) administered orally.
In the theophylline + BC group, rabbits were treated
orally with black catechu (264 mg/kg, p.o.) in normal
saline for 7 consecutive days and on the 8th day the-
ophylline (16 mg/kg) was administered orally one hour
after the last dose of the black catechu.
Blood sample collection
Animals were placed in individual restrainer. A polyeth-
ylene catheter (0.56 mm i.d., 0.98 mm o.d.) was insert-
ed into the marginal ear vein of each rabbit for collec-
tion of blood samples. Blood samples (1 mL) were col-
lected from the marginal vein of left pinna through an
indwelling vein catheter into heparinized vacutainer
tubes before theophylline administration and at 0.5, 1,
1.5, 2, 3, 4, 6, 8, 12, 24, and 36 h after dosing. Plasma
was immediately separated by centrifugation of blood
at 2500 g for 10 min and stored at－80 ℃ until quan-
titative analysis. In all experiments, equal volumes of
normal saline were injected through the cannula to re-
place the fluid loss.
Sample preparation
The protein precipitation method was used to prepare
samples for analysis. Plasma samples stored at －80 ℃
were thawed at room temperature and rotated for 30 s
to ensure homogeneity. To 200 µL of plasma sample,
20 µL of IS (250 µg/mL), 20 µL acetonitrile and 760 µL
of zinc sulphate solution (2%) were added to precipi-
tate protein of the sample. The samples were again ro-
tated gently for 1.5 min and then centrifuged for 10 min
at 12000 rpm. After centrifugation, 700 µL of clear su-
pernatant was transferred into HPLC vials. The 25 µL
of each sample was subjected to HPLC-UV analysis.27
Analysis was done using HPLC system (LC 2010C,
Shimadzu Corporation, Kyoto, Japan) equipped with
UV detector. The separation of theophylline was made
on a Waters® C18 column (µBondapakTM 5µm, 150 mm
× 3.9 mm i.d) using water/acetonitrile (96∶4 v/v) with
pH of 4.2 adjusted with glacial acetic acid as mobile
phase, pumped at a flow-rate of 1.0 mL/min. Detec-
tion was set at a wave length of 272 nm.
Pharmacokinetic analysis
Non-compartmental analysis was used to determine
the pharmacokinetic parameters of orally administered
theophylline. All data were obtained and subsequently
fed into PK software on Microsoft excel®. The maxi-
mum observed plasma concentration (Cmax) and the
time to reach the maximum observed plasma concen-
tration (Tmax), elimination rate constant (Kel) and
half-life (T1/2λ) were calculated. The parameters such as
total body clearance (CL/F), dose/area under the con-
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centration time profile curve from time 0 to infinity
(AUC0-¥) and mean residence time (MRT) which is the
ratio of area under the first moment curve time profile
curve from time 0 to 36 (AUMC0-36) and AUC0-36 were
calculated.
Statistical analysis
Data are presented as mean ± standard deviation ( xˉ ±
s). Differences in pharmacokinetic parameters of the-
ophylline alone and Co-administered with BC were as-
sessed by paired t-test using Graph Pad Prism version
3.00 for Windows (San Diego, CA, USA). Statistical
significance was assumed when P ≤ 0.05.
RESULTS
The estimated pharmacokinetic parameters of theoph-
ylline alone and co-administered with BC treatment
are listed in Table 1 and Figure 1. The control group
presented the Cmax and Tmax of (33.671 ± 1.551) mg/mL
and 1.500 h respectively, while the group co-adminis-
tered with BC produced Cmax and Tmax of (47.584 ±
3.527) mg/mL and 1.9 h respectively. Concurrent ad-
ministration of theophylline with BC showed obvious
increase in Cmax (P < 0.05) and Tmax of theophylline
compared with the control group, which is about
41.32% and 35.71% respectively. Co-administered
Figure 1 Concentrations versus time profile of theophylline following an oral administration in rabbits before and after pretreat-
ment with black catechu ( xˉ ± s, aP < 0.05)
Control group: rabbits were given saline water for 7 consecutive days and on the 8th day theophylline (16 mg/kg) administered
orally. Theophylline + BC group: rabbits were treated orally with black catechu (264 mg/kg, p.o.) in normal saline for 7 consecu-
tive days and on the 8th day theophylline (16 mg/kg) was administered orally one hour after the last dose of the black catechu.
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Parameter
Cmax (µg/mL)
Tmax (h)
Kel (h−1)
AUC0-t (µg·h-1·mL-1)
AUC0-∞ (µg·h-1·mL-1)
AUMC0-t (µg·h-1·mL-1)
AUMC0-∞ (µg·h-1·mL-1)
CL/F (mL/h)
T1/2λ (h)
Vd (mL)
MRT (h)
Control group (n = 5)
33.671±1.551
1.500±0.354
0.058±0.004
440.990±17.076
518.231±22.027
4966.779±328.223
7160.836±997.773
31.711±0.832
12.091±0.923
425.191±47.261
11.262±0.701
Theophylline + BC group (n = 5)
47.584±3.527a
1.900±0.223
0.068±0.008a
507.301±45.741a
558.202±42.991a
5414.505±786.613
7200.004±1654.563
28.185±2.882a
10.316±1.324a
346.075±35.822
10.621±0.781a
Notes: control group: rabbits were given saline water for 7 consecutive days and on the 8th day theophylline (16 mg/kg) administered oral-
ly. Theophylline + BC group: rabbits were treated orally with black catechu (264 mg/kg, p.o.) in normal saline for 7 consecutive days and
on the 8th day theophylline (16 mg/kg) was administered orally one hour after the last dose of the black catechu. BC: black catechu; Cmax:
maximum blood concentration; Tmax: time of peak concentration; Kel: elimination rate constant; AUC0-t: area under the concentration time
profile curve until last observation; AUC0-∞: area under the concentration time profile curve from time 0 to infinity; AUMC0-t: area under
the first moment curve time profile curve until last observation; AUMC0-∞: area under the first moment curve concentration time profile
curve from time 0 to infinity; CL/F: calculated oral clearance; T1/2λ: half-life; Vd: volume of distribution; MRT: mean residence time. Com-
pared with theophylline alone, aP < 0.05.
Table 1 Pharmacokinetic parameters of the control and theophylline + BC groups ( xˉ ± s)
a
a
a
a
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with BC significantly (P < 0.05) increased the mean
theophylline AUC0-t by 15.03% , from (440.990 ±
17.076) to (507.301 ± 45.741) µg·h-1·mL-1. It was al-
so observed that AUC0-∞ of the control group was
518.231 µg·h-1·mL-1, which was significantly (P <
0.05) lower than AUC0-∞ (558.202 µg·h-1·mL-1) pro-
duced by the theophylline + BC treated group. The rel-
ative bioavailability of theophylline was increased
(around 15.04%) when the drug co-administered with
BC.
A trend of reduction was observed in the calculated
oral clearance (CL/F) and volume of distribution. It
was observed that the calculated oral clearance was de-
creased by 11.13% (CL/F from 31.711 mL/h to
28.185 mL/h; P < 0.05), while the estimated oral vol-
ume of distribution was decreased by about 18.62%
[from (425.191 ± 47.261) to (346.075 ± 35.822) mL;
P < 0.05], although it was not statistically significant
(Table 1). While there was a marginal decrease in CL/
F in the theophylline + BC group as compared to the
control group with a statistical significance. These pa-
rameters show a decrease of T1/2λ from (12.091 ±
0.923) to (10.316 ± 1.324) h (P < 0.05), which is
about 14.67% in comparison to theophylline alone.
Overall, it was observed that there were increases in
Cmax, Tmax and AUC0-t, and decreases in CL/F and Vd in
the group pretreated with BC in comparison to the
control group.
DISCUSSION
Co-administration of some herbs may alter the pharma-
cokinetic profile of the concurrently administered
drug.12 The concurrent use of herbs may mimic, magni-
fy, or oppose the effect of drugs. The clinical conse-
quence of interactions may be lack of efficacy, toxic re-
actions, unexpected effects, unforeseen side effects, and
non-compliance, and it is therefore of major impor-
tance for patient outcome.28,29 The incidence of
herb-drug interactions have grown serious concern for
a narrow therapeutic index drug.30,31
BC contains high amount of tannins and flavonoids.18
A wide spectrum of compounds that have been isolat-
ed and characterized from BC include 4-hydroxybenzo-
ic acid, kaempferol, quercetin, 3,4',7-trihydroxyl-3',
5-dimethoxyflavone, catechin, rutin, isorhamnetin, epi-
catechin, afzelechin, epiafzelechin, mesquitol, ophioglo-
nin, aromadendrin and phenol.32
BC mainly comprised flavonoids and catechin demon-
strated anti-inflammatory activity by reducing the pro-
duction of pro-inflammatory eicosanoids.33 It has very
potent anti-microbial, anti-mycotic, hypotensive, hypo-
glycemic as well as potent antioxidant activity due to the
presence of tannins and flavonoids.33 In Indian subconti-
nent people (about 30%-46% ) used to consume BC
preparations such asGutka, PanMasala habitually.19,23-25,34
Taking the view of high prevalence use of BC in the
subcontinent we designed this study to know the effect
of BC on theophylline, a narrow therapeutic index
drug. To the best of our knowledge, this is the first re-
port which explored the effect of BC on the pharmaco-
kinetics of theophylline after oral administration in an
animal model. Our study has shown that BC interferes
with the theophylline pharmacokinetics to varying de-
gree. The BC treatment caused an increase in Cmax, Tmax,
AUC0-t and AUC0-∞. While parameters such as T1/2λ,
and Vd were decreased. The concurrent administration
of theophylline with BC showed an increase in Cmax
and Tmax of theophylline compared with the control
group,which is about 41.32%and35.71% respectively.
Approximately 90% of theophylline is metabolized in
liver by CYP1A.35 Theophylline undergoes 8-hydroxyl-
ation to 1,3, dimethyluric acid (60%-80% of parent
drug) with N-demethylation to form 1-methylxan-
thine (8%-24%) and 3-methylxanthine (5%-15%) by
the alternative routes.36
The increase in Cmax and Tmax and the decrease in oral
clearance of theophylline in BC treated rabbits may be
due to presence of polyphenols and flavonoids as they
are potent inhibitors of CYP1A.37 The increase in Cmax,
andTmax, and the decrease in oral clearance may lead to
increase in bioavailability of theophylline, leading to
toxic effect. These findings can be explained on the ba-
sis of inhibition of CYP1A enzymes in liver and intes-
tine following BC administration, thus decreasing drug
metabolism. It is reported that BC contains flavonoids
and tannins in majority.32 Quercetin and rutin, the
main flavonoids available in BC are reported as inhibi-
tor of CYP1A in intestinal cell lines.38 Other herb such
as Ginkgo biloba extract which contains similar constit-
uents as BC contains like kaempferol, quercetin also
shows potent inhibition of CYP1A. Thus we can con-
clude that it may be possible that BC inhibits CYP1A
activity.39 This study showed that BC could significant-
ly increase plasma concentration of theophylline possi-
bly due to inhibition of CYP1A activity. Further clini-
cal studies are needed to confirm the significance of
such interactions in human. Based on these results, pre-
caution should be exercised when administering BC
with theophylline.
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